Two State Council regulations took effect in China in May 2026, a few weeks apart. Together with CDE technical guidelines, the filing guides issued under Order 818, and China's human genetic resources rules, they set out how a gene-edited cell therapy gets from the lab to patients in China. Here is what the texts actually say.
Order No. 818, the Regulations on the Administration of Clinical Research and Clinical Translation of New Biomedical Technologies, was signed on September 28, 2025 and took effect on May 1, 2026. It covers medical techniques that act on human cells or molecules and are not yet in clinical use in China (Art. 3). That includes manipulating cells outside the body and returning them to a patient (Art. 8).
The route is hospital-based:
Moving into routine clinical use requires NHC approval (Art. 29). Only after that approval can hospitals charge for the technique (Art. 34). Running prohibited research carries fines of up to RMB 10 million, or 10 to 20 times any illegal gains above RMB 1 million (Art. 43).
Order 818 sits alongside the drug route. Article 55 says trials run to develop a drug or device stay under the Drug Administration Law. It also tasks the NHC and NMPA with jointly issuing guidance on where the line between the two routes falls.
Order No. 828, the revised Implementing Regulations of the Drug Administration Law, was signed on January 16, 2026 and took effect on May 15, 2026. For drug developers, these provisions stand out:
In July 2026, the CDE (NMPA's Center for Drug Evaluation) published its guideline on the scope and classification of cell therapy drugs (Notice 2026 No. 39). Cells genetically modified outside the body form their own subcategory of cell therapy drugs, developed and regulated along the drug pathway. The examples it gives include ex vivo CAR-T, ex vivo TCR-T and gene-modified hematopoietic stem cell products. In vivo approaches such as in vivo CAR-T fall outside the cell therapy category. The guideline also states that cell therapy development using Chinese human genetic resources must follow the genetic-resources rules covered below. It does not discuss Order 818.
The most specific text is CDE's nonclinical guideline for gene-modified cell therapy products (trial version, Notice 2021 No. 49). For cell products made with gene editing, it asks for in vitro on-target and off-target activity studies to confirm the editor's specificity. Sponsors must explain why they chose their evaluation strategy and how sensitive it is.
The guideline is direct about method. Computational prediction followed by deep sequencing of candidate sites "can be used," but the strategy "should still include in vitro whole-genome sequencing comparison" to show that no off-target editing has occurred at the potential off-target sites. Sponsors should also consider how species, cell state and cell type affect how well the nonclinical data predicts what happens in patients.
CDE's 2022 CMC guideline for ex vivo gene modification systems (trial version) adds manufacturing-side expectations:
The guideline describes itself as non-mandatory: applicants may propose alternative approaches with justification.
On April 30, 2026, the China National Center for Biotechnology Development (CNCBD) published technical filing guides for research under Order 818. They apply to clinical research "not for the purpose of drug registration" (§2), and two of them cover gene editing:
Both guides are version 1 and say they will be revised as the field develops.
China's Human Genetic Resources Regulations apply to two things (Art. 2):
The NHC has administered these rules since May 1, 2024, when Order No. 777 took responsibility away from the Ministry of Science and Technology. Four provisions matter most for foreign developers:
There is one exemption. International trials run to obtain marketing approval in China, where no materials leave the country, need a filing rather than an approval (Art. 22).
Taken together, the texts describe two separate routes. Order 818 covers hospital-based technologies; Order 828 and CDE guidance cover drug products. Both routes now have written off-target expectations: CDE's guidelines on the drug side, the CNCBD filing guides on the hospital side. China's genetic-resource rules govern where samples and sequencing data can go on either route.
If you're planning a gene-edited cell therapy program that touches China and want to talk through off-target confirmation, get in touch.
Chinese quotes are Countagen's translation.